Robson Dossa

Robson Dossa

Company: Arovella

Job title: Vice President


Invariant NKT Cells Unleashed: Building a Pipeline for Cutting-Edge Allogeneic Cell Therapies 11:30 am

• iNKT-CD19 CAR progressing from discovery towards first-in-human clinical trial against hematological malignancies. • Combining iNKT-CD19 CAR with a CD19-expressing oncolytic virus to target solid tumors. • Incorporation of CARs targeting solid tumors into the iNKT platform. Claudin 18.2 as a promising target against gastric and pancreatic tumors.Read more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.